MetaVia Inc Stock Price, News & Analysis

MetaVia (Nasdaq: MTVA) announced an accepted poster presentation on Vanoglipel (DA-1241), a GPR119 agonist, at the AASLD Liver Meeting 2025 in Washington, D.C., November 7–11, 2025.

The poster reports results from a 16-week randomized placebo-controlled trial in presumed MASH patients assessing hepatoprotective effects through improvements in inflammation and liver metabolism. Presenting author is Rohit Loomba, M.D., MHSc.

Poster details: Poster 4012, Session: Monday Poster Presenters Hall Hour; Date: Monday, November 10, 2025; Time: 1:00–2:00 pm ET; Location: Convention Center Hall DE, Level 2. A copy will be posted in the Posters section of MetaVia's website after the presentation.

MetaVia (Nasdaq: MTVA) announced two poster presentations on DA-1726, a dual oxyntomodulin analogue acting on GLP1R and GCGR, accepted for ObesityWeek® 2025 in Atlanta, November 4-7, 2025.

Both posters will be presented in Exhibit Hall A1 on Tuesday, November 4, 2025, 7:30-8:30 pm ET. Poster P-209 covers safety, tolerability, and pharmacokinetics from a Phase 1 study (presenting author Chris Fang, M.D.). Poster P-154 discusses DA-1726 as a therapy for obesity (presenting author Tae-Hyoung Kim, M.S.). Posters will be posted on the company website after presentation.

MetaVia (Nasdaq: MTVA) announced that President and CEO Hyung Heon Kim will present a company overview at the H.C. Wainwright Liver Disease Virtual Conference on October 21-22, 2025.

MetaVia also said CFO Marshall H. Woodworth will join one-on-one meetings with investors during the conference. Institutional investors registered for the event can request meetings via www.hcwevents.com. Investors wishing to meet outside the conference may contact Michael Miller at mmiller@rxir.com.

MetaVia (Nasdaq: MTVA), a clinical-stage biotech company specializing in cardiometabolic diseases, has announced its participation in several upcoming investor and industry conferences from September to October 2025.

CEO Hyung Heon Kim will attend the Wells Fargo Healthcare Conference (Sept 3-5), participate in a fireside chat at the H.C. Wainwright Global Investment Conference (Sept 8-10), present at the Obesity Science & Innovation Congress (Sept 16-17), and attend the Fierce Biotech Week (Oct 7-9). At the Obesity Science conference, Kim will showcase DA-1726, the company's dual oxyntomodulin analog agonist targeting GLP1R and GCGR for obesity treatment.

MetaVia (NASDAQ: MTVA) reported Q2 2025 financial results and provided updates on its cardiometabolic drug pipeline. The company dosed the first patient in an extended 8-week 48mg MAD cohort for DA-1726, their obesity treatment candidate. Previous 32mg dose cohort showed promising results with 4.3% average weight loss (max 6.3%) by Day 26.

The company also announced an AI-driven collaboration with Syntekabio to explore additional indications for DA-1241, their MASH treatment candidate. New preclinical data showed synergistic benefits when combining DA-1241 with Efruxifermin in reducing liver fat, inflammation, and fibrosis.

Financial highlights include $17.6 million cash position expected to fund operations into 2026, reduced R&D expenses to $2.3 million (down from $8.1 million YoY), and a net loss of $4.0 million ($0.26 per share) for Q2 2025.

MetaVia (NASDAQ:MTVA) has announced the extension of its Phase 1 clinical trial's 48 mg multiple ascending dose (MAD) cohort for DA-1726, its novel obesity treatment, from 4 to 8 weeks. The company has successfully administered the fifth weekly dose to the first patient.

The extension aims to evaluate longer-term early efficacy, safety, and explore the non-titrated maximum tolerated dose. Previously reported data from the 32 mg dose showed promising results, including mean weight loss of 4.3% (max 6.3%) by Day 26, early satiety in 83% of patients, and waist reductions up to 3.9 inches by Day 33.

DA-1726, a dual oxyntomodulin analog agonist, features a 3:1 balanced activation of GLP-1 and glucagon receptors, potentially offering better tolerability compared to current GLP-1 therapies. Top-line data from the extended trial is expected in Q4 2025.

MetaVia (Nasdaq: MTVA) has announced a strategic research collaboration with Syntekabio to expand therapeutic applications of DA-1241, their oral GPR119 agonist. The partnership will utilize Syntekabio's DeepMatcher® AI platform to screen DA-1241 against over 1,700 protein targets for new indications.

The collaboration follows positive Phase 2a results from a 16-week study involving 109 subjects, which demonstrated favorable safety and tolerability profiles, along with hepatoprotective and glucose-regulating effects in MASH patients. Initial insights from this AI-driven collaboration are expected later in 2025.

MetaVia (NASDAQ:MTVA) has initiated dosing in the 48 mg multiple ascending dose (MAD) cohort of its Phase 1 clinical trial for DA-1726, a novel dual oxyntomodulin analog agonist targeting obesity treatment. The trial's top-line data is expected in Q4 2025.

Previously reported data from the 32 mg dose showed promising results, including dose-dependent weight loss of 4.3% (mean) and 6.3% (max) by Day 26, with 83% of patients reporting early satiety. The drug demonstrated favorable cardiovascular safety and mild gastrointestinal side effects, potentially offering advantages over existing GLP-1 therapies that face high discontinuation rates.

The Phase 1 trial is studying safety, tolerability, and pharmacokinetics in obese subjects with BMI 30-45 kg/m², with subjects receiving 4 weekly administrations in a 6:3 randomization ratio.

MetaVia (MTVA) presented pre-clinical data showing that their GPR119 agonist DA-1241, when combined with Efruxifermin (EFX), demonstrates enhanced hepatoprotective effects in MASH treatment. The 12-week study in mice showed the combination therapy achieved significant improvements: 94% of mice achieved ≥2-point improvement in NAFLD activity score, with marked reductions in inflammatory markers (TNFα -58%, CXCL10 -56%, CCL2 -77%, galectin-3 -87%) and fibrotic markers (type 1 collagen α1 -72%, α-SMA -59%, TIMP1 -88%). While EFX alone reduced body weight by 17%, DA-1241 was weight-neutral, and the combination therapy showed additive benefits independent of weight loss. The data supports DA-1241's potential as part of a combination strategy for treating MASH.